Skip to main content
Equibles
CLDX logo

CLDX · Celldex Therapeutics, Inc.

Track CLDX — free

Use CLDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CLDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$36.90 -1.20 (-3.15%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$2.90B
Shares
78.53M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$36.90 Open$38.39 Day$36.84–38.59 52W close$22.58–44.87 Avg vol 30d791K Short int8.6M · 11.0% float · 12.2d Short vol58% Last earningsJul 21, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Feb 12, 2028 Est · unconfirmed · in 74 wks
Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$158,000
Trailing 12 months
Net income (TTM)
−$300.55M
Trailing 12 months
Revenue growth YoY
-97.0%
Year over year
Operating margin
-18,599.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$717.59M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+17.2%
Year over year · more shares
Price change (1Y)
+52.6%
Trailing year
Short interest
11.0%
Latest settlement · 12.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +16%
above
Price vs 50-day avg −6%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 64%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −13%
trailing
6-month return +19%
trailing
YTD return +36%
this year
Relative strength +2%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $39 › 200d $32 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +49 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.00% of float · ▲ +14.2% MoM · 12.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
258 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Weak
Revenue growth +88%
Y/Y
EPS growth −59%
Y/Y
Free cash flow $-213.7M
Quant / Vol
risk profile
High
Volatility 51%
annualized · 1-yr
Max drawdown −24%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+16% Bullish
Price vs 50-day avg
−6% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
64% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $39 › 200d $32 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +49 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.00% of float · ▲ +14.2% MoM · 12.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
258 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $23 Now $37 · 64% Range high $45
vs 200-day avg +16% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLDX
Celldex Therapeutics, Inc.
this stock
$2.90B +35.9% +87.8% — 11.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
258
% held
109.2%
Net QoQ
+12.6M sh
Top holder
WELLINGTON MANAGEMENT GRO…
Held Float
View
Held by Funds
Fund positions
253
View
Short & Settlement
Short Interest Rising
Shares short
8.6M
Days to cover
12.2d
Change
+1.1M sh
View
Short Volume
Short vol %
58%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
394
Value
$14.8K
As of
Aug 4, 2026
View
Off-Exchange
Off-exchange %
45.9%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.5M
Net income (FY)
$-258.8M
EPS diluted
$-3.90
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
11
View
Proposed Sales
Value
$121.2K
Shares
4.2K
Filed
Dec 4, 2025
View
Earnings & Events
Earnings Calls
Last call
Jul 21, 2026
View

Performance

5D 20D 120D MTD YTD
CLDX -6.3% -13.4% +19.4% -6.9% +35.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -5.1% -11.7% +1.6% -6.5% +23.8%
Key facts CIK 744218 CUSIP 15117B202 13F (30d) 140 filings 140 filers Visit website Investor relations